Our understanding of AAV is increasing
AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases1,2
AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart.2
Read moreRecent updates
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Achieving and Sustaining Remission while Reducing Organ Damage
ASN 2019
AAV Mechanism of Disease
See how the interaction between neutrophils and the alternative complement system are at the heart of the vasculitic process in AAV
More informationPatient videos
Patient videos - view stories from Catherine, Jeremy, John & Susan and Shanali on the patient experience page
Videos
Investigate AAV
Join the Rare Disease Investigation Team and put your expertise to the test in our interactive challenge. You’ll find it’s fully compatible with most desktop and mobile/tablet browsers (not for use on older versions of Internet Explorer or on Microsoft Edge)
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Jennette JC, et al. Arthritis Rheum 2013;65(1):1–11.
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
ERA-EDTA 2019 | EULAR 2019
NEW materials to download
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis. Poster >
High burden of disease for AAV patients in Germany - a claims study. Poster >
Economic burden of ANCA-associated vasculitis in Germany - a claims data study. Poster >
Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases. Poster >
Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data. Poster >
Renal damage in ANCA-associated vasculitis in incident and relapsing patients Slide deck >
ALSO NEW from UK Renal Week
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients. Poster >
Introduction to AAV
AAV is a rare, severe small vessel vasculitis that affects multiple organs and has a high acute mortality risk
Disease mechanism
The interaction between the activated alternative complement pathway, neutrophils and C5a is at the heart of vasculitic damage in AAV
Current therapies
Treatment has improved but treatment-related complications remain common
Investigate AAV
Take the interactive challenge to assess your understanding of AAV. Fully interactive version available on desktop only
Congress calendar
10th European Congress on Rheumatology, Autoimmunity and Orthopedics
16-17 October 2019 | Warsaw, Poland
American Society of Nephrology
5-10 November 2019 | Washington
American College of Rheumatology
8-13 November 2019 | Atlanta, Georgia
10th European Conference on Rare Diseases & Orphan Products
5 – 16 May 2020 | Stockholm, Sweden
Patient Support Organisations
France/Belgium
www.association-vascularites.org
Netherlands
www.vasculitis.nl
United Kingdom
www.vasculitis.org.uk